Get the Stockscreener App
2.81
0.18%
0.005
Mei Pharma Inc Stock (MEIP) Latest News
MEI Pharma (NASDAQ:MEIP) Earns Buy Rating from Analysts at StockNews.com - Defense World
Scientist pleads guilty to stealing trade secrets for Chinese pharma company - Fox28 Savannah
Layoff Tracker: Rentschler’s Cell and Gene Therapy Exit Could Affect Up to 30 - BioSpace
ROSEN, A LEADING LAW FIRM, Encourages Infinity Pharmaceuticals, - GuruFocus.com
MEI Pharma (NASDAQ:MEIP) Now Covered by StockNews.com - Defense World
B-cell Non-hodgkin Lymphoma Clinical and Non-Clinical - openPR
MEI Pharma (NASDAQ:MEIP) Coverage Initiated by Analysts at StockNews.com - Defense World
Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp - The Globe and Mail
A phase II study of zandelisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma: ME-401-K02 study - Wiley Online Library
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
Liquid Mushroom Market is Expected to Rise at CAGR of 6% to Reach US$ 15.74 Billion by 2034 | Fact.MR Report - GlobeNewswire Inc.
MEI Pharma stock hits 52-week low at $2.4 amid market challenges - Investing.com Canada
MEI Pharma stock hits 52-week low at $2.54 amid market challenges - Investing.com Australia
MEI Pharma (LTS:0JW9) 5-Day RSI : 36.09 (As of Dec. 05, 2024) - GuruFocus.com
MEIP (MEI Pharma) Financial Strength : 7 (As of Sep. 2024) - GuruFocus.com
Follicular Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
MEI Pharma (LTS:0JW9) Total Inventories : $0.00 Mil (As of Sep. 2024) - GuruFocus.com
Deal Dispatch: Starbucks Explores China Sale, PE Firms Saddle Snack Company With DebtAmcor (NYSE:AMCR), Berry Global Gr (NYSE:BERY) - Benzinga
Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul - Benzinga
MEI Pharma Reports Strategic Shift Amid Financial Losses - TipRanks
MEI Pharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com
MEI Pharma reports Q1 EPS ($1.20) vs. $8.46 last year - TipRanks
MEI Pharma Explores Strategic Sale Amid Cash Preservation Efforts, Reports $26.9M Cash Position | MEIP Stock News - StockTitan
Acute Myeloid Leukemia (AML) Treatment Market in APAC to Grow by USD 305.8 Million from 2024-2028, Driven by High Incidence and AI-Driven Market TransformationTechnavio - The Malaysian Reserve
Pre-market Movers: EVOK, HCTI, GLUE, MNPR... - RTTNews
Aardvark Therapeutics, Inc. agreed to acquire rights, title and interest in and to certain assets related to ME-344 from MEI Pharma, Inc. for $62.5 million. - Marketscreener.com
Data Readouts At EHA Congress 2021 (APTO, XFOR, GBT, CRIS…) - RTTNews
Stocks to Watch: MEI Pharma, Hawaiian Electric Industries - MarketWatch
MEI Shares Rise After Entering Asset Purchase Agreement Valued at Up to $62 Million - MarketWatch
MEI Pharma postpones special meeting to vote on Infinity deal until July 23 - MSN
MEIP (MEI Pharma) Free Cash Flow per Share : $-7.57 (TTM As of Jun. 2024) - GuruFocus.com
Post Polycythemia Vera Myelofibrosis Market: Holistic - openPR
Ampio Pharmaceuticals (NYSE:AMPE) Coverage Initiated by Analysts at StockNews.com - Defense World
MEI Pharma stock hits 52-week low at $2.72 amid market challenges - Investing.com India
MEI Pharma stock hits 52-week low at $2.72 amid market challenges By Investing.com - Investing.com South Africa
Acute Myeloid Leukemia Market Trends, Key Drivers, Opportunities, Leading Players And Forecast To 2033 - WhaTech
Histone Deacetylase 2 Industry Forecast (2024-2034) Under Inflation - Apiculture Market: Report ...
Myelodysplastic Syndrome Drugs Market Research Explores Size, Market Competitive Landscape, Business Growth... - WhaTech
Chronic Lymphocytic Leukemia Treatment Market Advancements Highlighted by Comprehensive Analysis, Advanceme... - WhaTech
Follicular Lymphoma Treatment Market Insights Discussed Regarding Size, Trends, and Overview Report 2024-2033 - WhaTech
MEI Pharma reviews strategic options amid fiscal changes - Investing.com India
MEI Pharma confirms continuation of evaluation of strategic alternatives - TipRanks
MEI Pharma Reports Fiscal Year End 2024 Cash Position - The Bakersfield Californian
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):